News

A new platform that optimises drug combinations for the treatment of multiple myeloma has been created. The developers hope that the computational quadratic phenotypic optimisation platform (QPOP) could help improve clinical outcomes in people who have become resistant to standard therapies. The condition is frequently treated with combination therapies that include bortezomib, a first-line drug with promising response rates. However, most patients end up relapsing due to the development of resistance against bortezomib, which has highlighted a need to identify secondary combination treatments that can overcome or forestall therapeutic resistance. Masturah Rashid, from the National University of Singapore, and colleague...